Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs

International Journal of Hematology

Volumn 104, Issue 3, 2016, Pages 293-299

  Ito, Takumi ^a,b   Handa, Hiroshi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Cereblon; IMiDs; Myeloma; Thalidomide; Ubiquitin

Indexed keywords

CEREBLON; IMMUNOMODULATING AGENT; LENALIDOMIDE; PEPTIDES AND PROTEINS; POMALIDOMIDE; THALIDOMIDE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CRBN PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; PEPTIDE HYDROLASE; UBIQUITIN PROTEIN LIGASE;

5Q- SYNDROME; ANTINEOPLASTIC ACTIVITY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME SPECIFICITY; HUMAN; IMMUNOMODULATION; LIMB DEFORMITY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ANALYSIS; TERATOGENESIS; TERATOGENICITY; THERAPY EFFECT; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; MOLECULAR TARGETED THERAPY; PEPTIDE HYDROLASES; SUBSTRATE SPECIFICITY; UBIQUITIN-PROTEIN LIGASES;

EID: 84979702661     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-016-2073-4     Document Type: Review

References (45)

1. McBride WG. Thalidomide embryopathy. Teratology. 1977;16:79–82.
2. Lenz W. A short history of thalidomide embryopathy. Teratology. 1988;38:203–15.
3. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314–22.
4. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet. 2004;363:1802–11.
5. Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol. 2007;39:1489–99.
6. Vargesson N. Thalidomide-induced limb defects: resolving a 50-year-old puzzle. BioEssays. 2009;31:1327–36.
7. Ito T, Ando H, Handa H. Teratogenic effects of thalidomide: molecular mechanisms. Cell Mol Life Sci. 2012;68:1569–79.
8. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther. 1965;6:303–6.
9. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173:699–703.
10. D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082–5.
11. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–71.
12. Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther. 1999;21:319–30.
13. Ooba N, Sato T, Watanabe H, Kubota K. Resolving a double standard for risk management of thalidomide: an evaluation of two different risk management programmes in Japan. Drug Saf. 2010;33:35–45.
14. Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett. 1999;9:1625–30.
15. Sakamoto S, Hatakeyama M, Ito T, Handa H. Tools and methodologies capable of isolating and identifying a target molecule for a bioactive compound. Bioorg Med Chem. 2012;20:1990–2001.
16. Groisman R, Polanowska J, Kuraoka I, et al. The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell. 2003;113:357–67.
17. Lee J, Zhou P. DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol Cell. 2007;26:775–80.
18. Lydeard JR, Schulman BA, Harper JW. Building and remodelling Cullin-RING E3 ubiquitin ligases. EMBO Rep. 2013;14:1050–61.
19. Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345–50.
20. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009;69:7347–56.
21. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454:226–31.
22. Lopez-Girona A, Heintel D, Zhang LH et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol. 2011;154:325–36.
23. Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118:4771–9.
24. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326–35.
25. Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2013;343:301–5.
26. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2013;343:305–9.
27. Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol. 2014;164:811–21.
28. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–65.
29. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549–57.
30. Kronke J, Fink EC, Hollenbach PW, et al. Lenalidomide induces ubiquitination and degradation of Ck1αlpha in del(5q) MDS. Nature. 2015;523:183–8.
31. Jaras M, Miller PG, Chu LP, et al. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med. 2014;211:605–12.
32. Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29:1971–9.
33. Fischer ES, Bohm K, Lydeard JR, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014;512:49–53.
34. Chamberlain PP, Lopez-Girona A, Miller K, et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014;21:803–9.
35. Li T, Chen X, Garbutt KC, Zhou P, Zheng N. Structure of DDB1 in complex with a paramyxovirus V protein: viral hijack of a propeller cluster in ubiquitin ligase. Cell. 2006;124:105–17.
36. Angers S, Li T, Yi X, MacCoss MJ, Moon RT, Zheng N. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature. 2006;443:590–3.
37. Yang Y, Shaffer AL, 3rd, Emre NC et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21:723–37.
38. Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, Chopra R. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2013;160:487–502.
39. Hagner PR, Man HW, Fontanillo C, et al. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood. 2015;126:779–89.
40. CRBN ubiquitin ligase. Nature. 2016;. doi:10.1038/nature18611.
41. Hartmann MD, Boichenko I, Coles M, Zanini F, Lupas AN. Hernandez Alvarez B. Thalidomide mimics uridine binding to an aromatic cage in cereblon. J Struct Biol. 2014;188:225–32.
42. Nguyen TV, Lee JE, Sweredoski MJ, et al. Glutamine triggers acetylation-dependent degradation of glutamine synthetase via the thalidomide receptor cereblon. Mol Cell. 2016;61:809–20.
43. Winter GE, Buckley DL, Paulk J, et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348:1376–81.
44. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478:524–8.
45. Lai AC, Toure M, Hellerschmied D, et al. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016;55:807–10.